| Nov 14 |
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
|
| Nov 13 |
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
|
| Oct 22 |
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
|
| Oct 16 |
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
| Oct 16 |
Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth
|
| Oct 9 |
Lexaria Bioscience Launches Human Study of DehydraTECH-Processed Tirzepatide
|
| Oct 9 |
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
|
| Oct 8 |
Lexaria Updates Current GLP-1 Market
|
| Oct 1 |
Lexaria Appoints Michael Shankman as Chief Financial Officer
|
| Sep 27 |
Lexaria Bioscience Receives Approval From Independent Review Board for Pilot Study of Tirzepatide
|
